Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

CRISPR Therapeutics (CRSP)

NASDAQ: CRSP · Biotechnology—Gene Editing · Zug,

Our rating: Cautious

Cautious reaffirmed at $49.99, moderate conviction, November 3, 2026.

Breaks if: The cautious call is proved wrong if Casgevy-related revenue — royalties and milestones combined — exceeds $60M in any single reported quarter within the next four quarters. That level of commercial throughput would signal the slow-ramp thesis has broken and would warrant reassessing to at least Neutral. On the price side, if CRSP holds above $70 for six consecutive months without a corresponding revenue inflection, the market is pricing a pipeline catalyst not yet visible in the filings and the call requires re-examination.

Key figures

Market value$3.8B
Revenue, last 12 months$25M
Net income, last 12 months−$456M
Free cash flow, last 12 months−$377M
Price to earningsn/a
Free cash flow yield−9.9%
Dividend yield0.0%
Operating margin−2114.8%
Return on equity−25.6%
Beta to the S&P 5001.46
Volatility, annualized58.3%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$13M1325.1%$-1.15−$90M
June 30, 2026$10M1041.4%$-0.94−$84M
March 31, 2026$1M68.6%$-1.28−$109M
December 31, 2025$864000.00−97.6%$-1.35−$93M
September 30, 2025$889000.0047.7%$-1.17−$85M
June 30, 2025$892000.0072.5%$-2.40−$114M
March 31, 2025$865000.0071.6%$-1.58−$54M
December 31, 2024$36M−82.3%$-0.42−$50M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

21 ledger entries and 48 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.